Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer

Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer

Abstract Purpose Ra-223 dichloride (223Ra, Xofigo®) is used for treatment of patients suffering from castration-resistant metastatic prostate cancer. The objective of this work was to apply the most recent biokinetic model for radium and its progeny to show their radiopharmacokinetic behaviour. Orga...

Full description

Bibliographic Details
Main Authors:	Vera Höllriegl, Nina Petoussi-Henss, Kerstin Hürkamp, Juan Camilo Ocampo Ramos, Wei Bo Li
Format:	Article
Language:	English
Published:	SpringerOpen 2021-06-01
Series:	EJNMMI Physics
Subjects:	Radiopharmaceutical Biokinetic models 223Ra Internal dose Radionuclide therapy
Online Access:	https://doi.org/10.1186/s40658-021-00388-1

Similar Items

Determinants of target absorbed dose in radionuclide therapy
by: Heribert Hänscheid, et al.
Published: (2023-02-01)

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
by: Tai-Lung Cha, et al.
Published: (2017-11-01)

The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study
by: Rosa Sciuto, et al.
Published: (2021-09-01)

Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01)

Comparing absorbed doses and radiation risk of the α-emitting bone-seekers [223Ra]RaCl2 and [224Ra]RaCl2
by: Michael Lassmann, et al.
Published: (2023-01-01)

Еfficiacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration- resistant prostate cancer and bone metastases
by: LOU Jingjing, et al.
Published: (2021-12-01)

Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
by: Asta Juzeniene, et al.
Published: (2023-01-01)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
by: Kim van der Zande, et al.
Published: (2021-08-01)

Estimation of the lower limits for feasible Ra-223 SPECT imaging: a Monte Carlo simulation study
by: Akihiko Takahashi, et al.
Published: (2021-07-01)

Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
by: Anna Maria Mangano, et al.
Published: (2018-02-01)

Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer
by: Amanjot Sidhu, et al.
Published: (2023-08-01)

Quantitative measurement of 219Rn radioactivity in exhaled breath from patients with bone metastasis of castration-resistant prostate cancer treated with 223RaCl2
by: Kazuhiro Ooe, et al.
Published: (2019-07-01)

Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines
by: Andris Abramenkovs, et al.
Published: (2022-12-01)

Deconvolution method to split up X-ray peaks emitted by 223Ra
by: Rafael Figueiredo Pohlmann Simões, et al.
Published: (2018-01-01)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
by: Monica Vidal, et al.

Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
by: Anniina Hyväkkä, et al.
Published: (2023-02-01)

Development of a methodology for the analysis of radionuclide impurities in radiopharmaceuticals by gamma-ray spectrometry
by: Eduardo Bonfim De Paula, et al.
Published: (2017-11-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Radioisotopes in management of metastatic prostate cancer
by: Amar Raval, et al.
Published: (2016-01-01)

Hydroxyapatite and Titanium Dioxide Nanoparticles: Radiolabelling and In Vitro Stability of Prospective Theranostic Nanocarriers for <sup>223</sup>Ra and <sup>99m</sup>Tc
by: Petra Suchánková, et al.
Published: (2020-08-01)

Study of <sup>211</sup>Bi and <sup>211</sup>Pb Recoils Release from <sup>223</sup>Ra Labelled TiO<sub>2</sub> Nanoparticles
by: Ján Kozempel, et al.
Published: (2022-12-01)

Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Yasuo Oguma, et al.
Published: (2022-09-01)

[223Ra] RaCl2 nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era
by: Yang Yang, et al.
Published: (2022-12-01)

Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
by: Gayed I, et al.
Published: (2018-09-01)

The inhibiting effect of alpha-based TARE on embolized vessels and neovascularization
by: Qianqian Tong, et al.
Published: (2022-10-01)

Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis
by: Junru Chen, et al.
Published: (2022-01-01)

A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy
by: Uwe Holzwarth, et al.
Published: (2018-05-01)

Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment
by: Frantellizzi Viviana, et al.
Published: (2019-12-01)

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis
by: Xiaohui Zeng, et al.
Published: (2022-10-01)

Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases
by: Chirayu M. Patel, et al.
Published: (2021-04-01)

Possible Impurities in Radiopharmaceuticals and Corresponding Test Methods
by: G. E. Kodina, et al.
Published: (2022-10-01)

Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer
by: Kazuya Takeda, et al.
Published: (2023-01-01)

Patient organ and effective dose estimation in radionuclide therapy with <sup>223</sup>Ra -dichloride
by: L. A. Chipiga, et al.
Published: (2020-12-01)

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT
by: Kalevi Kairemo, et al.
Published: (2015-10-01)

PSMA and 18F-FDG PET Imaging in the Treatment of Metastatic Prostate Cancer with 223Ra: Initial Application and Experience
by: HU Guilan, et al.
Published: (2023-07-01)

Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study
by: Matteo Bauckneht, et al.
Published: (2022-03-01)

Approach to radionuclide therapy dosimetry planning
by: Yu.V. Lysak, et al.
Published: (2016-12-01)

Analysis of Current Rules and Regulations for Preclinical Studies of Radiopharmaceuticals
by: A. S. Lunev, et al.
Published: (2024-02-01)

Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy
by: Cyprine Neba Funeh, et al.
Published: (2023-04-01)